ALS Canada to Fund New Clinical Trial in ALS with Ice Bucket Challenge Donations

The ALS community has been eagerly awaiting updates on the use of Ice Bucket Challenge dollars. The ALS Society of Canada, with matching funds from Brain Canada and the Government of Canada, has now announced its first research grant using the Canadian ‘Ice Bucket’ funds, which totaled approximately $16M. The grant will fund a new clinical trial of pimozide in ALS as well as development of a companion biomarker test. Pimozide is already approved in Canada for treating schizophrenia and Tourette’s syndrome, and is thought to act by stabilizing the neuromuscular junction. A small clinical trial in Poland has previously reported benefits with pimozide (Szczudlik et al., 1998), and positive effects on disease progression have also been demonstrated in ALS mouse models. More information about the study will be released when patient recruitment begins.

The ALS community has been eagerly awaiting updates on the use of Ice Bucket Challenge dollars. The ALS Society of Canada, with matching funds from Brain Canada and the Government of Canada, has now announced its first research grant using the Canadian ‘Ice Bucket’ funds, which totaled approximately $16M. The grant will fund a new clinical trial of pimozide in ALS as well as development of a companion biomarker test. Pimozide is already approved in Canada for treating schizophrenia and Tourette’s syndrome, and is thought to act by stabilizing the neuromuscular junction. A small clinical trial in Poland has previously reported benefits with pimozide (Szczudlik et al., 1998), and positive effects on disease progression have also been demonstrated in ALS mouse models. More information about the study will be released when patient recruitment begins.

Click here to read more.

disease-als topic-clinical topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail